CLINICAL TRIAL article
Front. Neurol.
Sec. Movement Disorders
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1637184
Modulation of Brain Activity and Tremor Severity by NeuroEpo in Parkinson's Patients with Varying Tremor Amplitudes
Provisionally accepted
Ahmed Asef Jiman
Eyad Attar*- King Abdulaziz University, Jeddah, Saudi Arabia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Tremors, particularly those related to Parkinson's disease (PD), significantly affect quality of life. In this study, we inspected the effects of NeuroEpo versus placebo on brain function and tremor inhibition in patients with high-amplitude tremors (HAT) and low-amplitude tremors (LAT). Objectives: To assess the efficacy of NeuroEpo in enhancing coherence and power spectral density (PSD) relative to tremor severity, and to explore differences in stimulation parameters and medication requirements between patients with HAT and LAT. Methods: A double-blind randomized controlled trial was conducted on 16 participants diagnosed with PD. Participants were stratified into the HAT (n = 8) and LAT (n = 8) groups. Deep brain stimulation (DBS) parameters were individualized, and participants received either NeuroEpo or a placebo. The study was approved by the IRP on October 2, 2001, and all research participants gave informed consent. This research was conducted at the University of Quebec at Montreal, McGill University in Montreal, Quebec, Canada, and CHU de Bordeaux at Hôpital du Haut-Lévêque, Pessac, France. Data were obtained from authentic online platforms using DOI-referenced sources. Outcome measures included tremor severity, brain activity via EEG, and medication dosage. Results: NeuroEpo treatment produced a significant increase in coherence and PSD, particularly in the 20–21 Hz frequency band, compared with placebo. Patients with LAT required higher stimulation intensities and medication doses than those with HAT, suggesting a more complex disease profile. The combination of NeuroEpo and DBS resulted in improved both motor and cognitive functions. A two-way ANOVA indicated a significant main effect of treatment (p < 0.05), with the NeuroEpo group exhibiting a significantly greater PSD than the placebo group. Conclusion: NeuroEpo may provide an adjuvant therapeutic aid for the control of tremor and improvement in brain function in PD patients. Customized treatment approaches incorporating tremor amplitude may improve therapeutic benefit and patient well-being. Future research should follow up on the long-term psychosocial effects of combined interventions.
Keywords: Parkinson's disease, NeuroEPO, Tremor characteristics, Motor function, Cognitive Function, deep brain stimulation (DBS), Neuronal activity, High Amplitude Tremor (HAT)
Received: 02 Jun 2025; Accepted: 14 Aug 2025.
Copyright: © 2025 Jiman and Attar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Eyad Attar, King Abdulaziz University, Jeddah, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.